Welcome to our dedicated page for Orthopedia news (Ticker: KIDS), a resource for investors and traders seeking the latest updates and insights on Orthopedia stock.
OrthoPediatrics Corp. develops and commercializes medical devices for pediatric orthopedics, with products used in trauma and deformity, scoliosis, sports medicine and related procedures. Company news commonly covers quarterly financial results, revenue by product category, domestic and international sales trends, cash-flow metrics and updates to financial guidance.
Recurring product and market updates include specialty bracing, spine and deformity correction systems, implants, instruments and enabling technologies for pediatric care. Announcements also include investor conference participation and portfolio additions such as hospital-based traction systems and other products aimed at children with orthopedic conditions.
Telos Partners LLC, a subsidiary of OrthoPediatrics Corp. (NASDAQ: KIDS), has appointed Erik Waldorff, PhD, as Director of Science & Innovation. With over 17 years of experience in orthopedic and medical device development, Waldorff aims to enhance Telos' scientific services and support commercialization objectives. His background in Biomedical Engineering, coupled with business acumen, positions him to drive innovative solutions for client partners. This leadership change is expected to strengthen Telos's offerings in regulatory, reimbursement, and clinician adoption fields.
OrthoPediatrics Corp. (Nasdaq: KIDS) announced participation in three virtual investor conferences in November 2020. Key executives, including CEO Mark Throdahl and COO Fred Hite, will represent the company. The events include the Credit Suisse 29th Annual Virtual Healthcare Conference on November 11, Stifel 2020 Virtual Healthcare Conference on November 18, and Canaccord Genuity 2020 Virtual MedTech & Diagnostics Forum on November 19. Investors can access the audio webcast on OrthoPediatrics' investor relations site.
OrthoPediatrics Corp. (NASDAQ: KIDS) will release its third quarter 2020 financial results on November 4, 2020, after the market closes. A conference call to discuss these results is scheduled for November 5, 2020, at 8:00 a.m. ET. Interested participants can join the call using the provided domestic and international dial-in numbers. OrthoPediatrics, founded in 2006, focuses on pediatric orthopedics, offering 35 surgical systems across multiple categories and serving markets in the U.S. and 43 other countries.
OrthoPediatrics Corp. (KIDS) announced its support for the 3rd Annual PediOrtho WEST Resident Education Course, scheduled for October 16-17 in Sacramento, California. The course aims to provide orthopedic residents with essential training in pediatric orthopedic techniques through both lectures and hands-on labs, facilitated by expert surgeons. President David Bailey emphasized the company's commitment to advancing pediatric orthopedic education globally, enhancing outcomes for aspiring surgeons.
OrthoPediatrics Corp. (Nasdaq: KIDS) announces continued support for the Scoliosis Research Society (SRS) with Gold Level sponsorship for its 55th Annual Meeting, running virtually from September 9-13. Additionally, the company will be a Platinum Level Sponsor for the American Academy for Cerebral Palsy and Developmental Medicine (AACPDM) 74th Annual Meeting from September 23-26. OrthoPediatrics will offer educational grants and scholarships for physicians attending these events, contributing to discussions and showcasing its products through virtual exhibits.
OrthoPediatrics Corp. (Nasdaq: KIDS) announced participation in the Morgan Stanley 18th Annual Global Healthcare Conference on September 15, 2020. Key executives, including CEO Mark Throdahl and CFO Fred Hite, will engage in a fireside chat and one-on-one meetings starting at 4:15 PM ET. The event will take place virtually, with an audio webcast accessible on the company’s investor relations website. OrthoPediatrics specializes in pediatric orthopedic products, boasting 35 surgical systems for trauma, scoliosis, and sports medicine across 43 countries.
OrthoPediatrics Corp. (Nasdaq: KIDS) announced the completion of its 1,000th surgery using the Pediatric Nailing Platform | FEMUR (PNP | FEMUR), a system designed for pediatric femur fracture treatment. This innovative intramedullary nailing system, which received FDA 510(k) clearance in 2018, addresses specific anatomical needs of children and adolescents. With a comprehensive range of sizes and instrumentation, the PNP system represents OrthoPediatrics' commitment to improving pediatric orthopedic solutions, building on nearly a decade of learning from its original PediNail system.
OrthoPediatrics Corp. (Nasdaq: KIDS) has announced its sponsorship for the virtual 30th Annual Baltimore Limb Deformity Course (BLDC) on August 29-30, 2020. The company will provide scholarships for residents and fellows to access the course. Utilizing its DocMatter and VuMedi platforms, OrthoPediatrics will share educational video content on its innovative Orthex frame, aimed at correcting limb deformities. CEO Mark Throdahl emphasized the importance of BLDC for pediatric surgeons and the effectiveness of virtual interactions in advancing orthopedic care for children.
OrthoPediatrics Corp. (Nasdaq: KIDS) announced participation in the 5th Annual Needham Virtual Med Tech 1x1 Conference. CEO Mark Throdahl, COO Fred Hite, and President Dave Bailey will host virtual investor meetings on August 17, 2020. Interested investors can schedule one-on-one calls by contacting their Needham representative or Emma Poalillo at The Ruth Group.
Founded in 2006, OrthoPediatrics focuses on pediatric orthopedics, offering 35 surgical systems across trauma, scoliosis, and sports medicine categories. The company operates globally, serving the U.S. and 43 countries.
OrthoPediatrics Corp. (Nasdaq: KIDS) reported a 25.3% decline in total revenue for the second quarter of 2020, amounting to $13.6 million, largely due to the effects of the COVID-19 pandemic. U.S. revenue decreased by 12.3% to $12.1 million, while international revenue plummeted 66.8% to $1.4 million. Despite challenges, the company initiated the U.S. launch of the ApiFix system and expanded its sales team by 7.9%. Operating loss increased to ($7.0 million), compared to ($1.8 million) last year, while net loss was ($9.4 million), leading to a net loss per share of ($0.54).